How should a UK deep-tech founder sequence funding?
Validate with ICURe or a Catapult scoping project, then layer grants, equity and reliefs.
Key takeaway
Validate with ICURe or a Catapult scoping project, then layer grants, equity and reliefs. This guide weighs British Patient Capital, ICURe (Innovation-to-Commercialisation of University Research), Innovate UK Smart Grants against your stage, funding type and timeline using verified FundingAtlas data, and explains when each is the right call.
The question
Validate with ICURe or a Catapult scoping project, then layer grants, equity and reliefs.
Key considerations
The factors that should shape your decision before you commit operator hours to an application.
| Funding stage | growth, idea, any, startup |
|---|---|
| Funding type | equity, grant, tax_incentive |
| Funding amount | British Patient Capital: Funding levels vary and should be confirmed through the official scheme guidance. • ICURe (Innovation-to-Commercialisation of University Research): Funding levels vary and should be confirmed through the official scheme guidance. • Innovate UK Smart Grants: £100k–£2m • Seed Enterprise Investment Scheme (SEIS): Up to £250k raised |
| Eligibility | High-growth UK companies backed by funds in the British Patient Capital portfolio. No direct applications. |
| Timeline | There is no central British Patient Capital application. Engagement with each underlying fund typically runs 3–9 months from first meeting to term sheet, plus a further 4–12 weeks of diligence and legals to close. Plan investor processes well in advance of when you need the cash. |
| Region | Some programmes are England-only, others run across the devolved nations or are restricted to combined-authority footprints. Check each official source. |
Recommended route
Most successful deep-tech businesses combine early market validation (ICURe / accelerator), grant-funded R&D (Innovate UK), tax relief (RDEC/ERIS) and patient equity (EIS-led angels, then growth equity, then patient capital). Sequence matters more than total grant value.
Alternative routes
Where the primary recommendation is not the right fit, these are the programmes most commonly considered alongside it.
- ICURe (Innovation-to-Commercialisation of University Research)
grant · Funding levels vary and should be confirmed through the official scheme guidance.
- Innovate UK Smart Grants
grant · £100k–£2m
- Seed Enterprise Investment Scheme (SEIS)
tax_incentive · Up to £250k raised
Common mistakes
- Starting with the largest scheme rather than the highest-fit scheme.
- Treating funding as a one-off project rather than a 24-month strategy.
- Underestimating the documentation effort: prior trading, prior R&D, finance pack.
- Missing the interaction between grant income and downstream R&D tax relief.
- Engaging a contingent-fee broker before checking whether the scheme is broker-eligible.
- Self-selecting out of a programme based on an optimistic read of eligibility.
Decision checklist
- Confirm your business stage, region and headcount against scheme thresholds.
- Map the next 24 months of funding need before applying to any one programme.
- Identify the official source for each programme on your shortlist.
- Quantify match-funding and staged-drawdown impact on cashflow.
- Check subsidy-control / de minimis ceilings across stacked awards.
- Model the interaction with R&D tax relief on subsidised costs.
- Decide whether the assessment timeline fits your delivery plan.
- Schedule the application in the calendar before committing operator hours.
Frequently asked questions
- What is this decision guide about?
- Validate with ICURe or a Catapult scoping project, then layer grants, equity and reliefs.
- Which funding stage does this guide cover?
- Programmes referenced here target: growth, idea, any, startup.
- What types of funding are compared?
- This guide considers: equity, grant, tax_incentive.
- How much funding could I access?
- British Patient Capital: Funding levels vary and should be confirmed through the official scheme guidance.. ICURe (Innovation-to-Commercialisation of University Research): Funding levels vary and should be confirmed through the official scheme guidance.. Innovate UK Smart Grants: £100k–£2m. Seed Enterprise Investment Scheme (SEIS): Up to £250k raised.
- Who is eligible for the recommended routes?
- High-growth UK companies backed by funds in the British Patient Capital portfolio. No direct applications.
- How long will it take to receive funding?
- There is no central British Patient Capital application. Engagement with each underlying fund typically runs 3–9 months from first meeting to term sheet, plus a further 4–12 weeks of diligence and legals to close. Plan investor processes well in advance of when you need the cash.
- Can I apply to more than one of these programmes?
- Some combinations are permitted, others are restricted by subsidy-control rules or scheme-specific exclusivity clauses. Refer to the latest programme guidance before stacking applications.
- Will receiving a grant affect my R&D tax relief claim?
- It can. Grant-subsidised R&D expenditure is often relievable only at a reduced rate, and the interaction depends on which scheme funded which costs. FundingAtlas could not verify the interaction for every combination; confirm with a qualified adviser.
- What if my situation does not match any of the recommended routes?
- Use the Funding Finder to build a personalised shortlist, or request a Funding Strategy Review for a reviewer-led assessment.
- Where do I find the official source for each programme?
- British Patient Capital: https://www.britishpatientcapital.co.uk/our-portfolio/ — ICURe (Innovation-to-Commercialisation of University Research): https://www.icureprogramme.com/ — Innovate UK Smart Grants: https://apply-for-innovation-funding.service.gov.uk/competition/search — Seed Enterprise Investment Scheme (SEIS): https://www.gov.uk/guidance/venture-capital-schemes-apply-for-the-seed-enterprise-investment-scheme
Next steps
Related grants
More decision guides